Imagen de Portada

The US Food and Drug administration has approved resmetirom as the first drug to treat metabolic dysfunction‐associated steatohepatitis (MASH)

Fuente: Wiley Open Access

Guardado en:

Detalles Bibliográficos
Autor principal:	Iskandar Idris
Formato:	Artículo Open Access
Publicado:	Wiley 2024
Materias:	Diabetes, Obesity and Metabolism Now
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Increased expression of the protein Kallistatin after weight loss induces beneficial metabolic effects: A potential new therapeutic target?
por: Iskandar Idris
Publicado: (2024)

Glucagon like peptide‐1 (GLP‐1) therapy is associated with reduced risk of developing cirrhosis and liver cancer in people with type 2 diabetes with chronic liver disease
por: Iskandar Idris
Publicado: (2024)

Real world data showed that the dual GLP gip agonist, Tirzepatide is associated with lower mortality, cardiovascular events and adverse kidney events compared with GLP‐1 analogue
por: Iskandar Idris
Publicado: (2024)

Hybrid closed‐loop therapy significantly improved maternal glucose control during pregnancy complicated by type 1 diabetes
por: Iskandar Idris
Publicado: (2024)

The glucagon like peptide‐1 linked to nonarteritic anterior ischemic optic neuropathy
por: Iskandar Idris
Publicado: (2024)

Potential role of glucagon like peptide (GLP)‐1 receptor agonist to reduce risk of colorectal cancer?
por: Iskandar Idris
Publicado: (2024)

Tirzepatide shown to be effective at reducing sleep disturbances in patients with obstructive sleep apnoea
por: Iskandar Idris
Publicado: (2024)

Can diet and exercise intervention prevent type 2 diabetes in individuals with a high genetic risk?
por: Iskandar Idris
Publicado: (2024)

Appropriate timing of exercise for adults with obesity including those with type 2 diabetes
por: Iskandar Idris
Publicado: (2024)

Extension study from DIRECT showed ongoing remission rate from type 2 diabetes in some patient following very low calorie diet at 5 years
por: Iskandar Idris
Publicado: (2024)

Adults who are overweight or obese may experience greater pain intensity compared with normal weight individuals?
por: Iskandar Idris
Publicado: (2024)

Tirzepatide shown to improve clinical outcomes for patients with heart failure with preserved ejection fraction (HFpEF) and obesity
por: Iskandar Idris
Publicado: (2024)

Potential new therapies to preserve lean muscle mass loss when used in combination with glucagon‐like peptide 1 (GLP‐1) receptor agonist being studied
por: Iskandar Idris
Publicado: (2024)

Epigenetic changes shown to cause type 2 diabetes
por: Iskandar Idris
Publicado: (2024)

Real world study provided reassurance of the safety of GLP‐1 therapy on mental health and suicide risk
por: Iskandar Idris
Publicado: (2024)

Precision medicine approach to detect obese people who are at high risk of developing diabetes
por: Iskandar Idris
Publicado: (2024)

Increasing excess to weight loss injection shown to save thousands of lives a year
por: Iskandar Idris
Publicado: (2024)

Fenofibrate shown to reduce progression of diabetic retinopathy
por: Iskandar Idris
Publicado: (2024)

Issue Information
Publicado: (2024)

Issue Information
Publicado: (2024)

Issue Information
Publicado: (2024)

Issue Information
Publicado: (2024)

Issue Information
Publicado: (2024)

Issue Information
Publicado: (2024)

Issue Information
Publicado: (2024)

Issue Information
Publicado: (2024)

Is the combination of resmetirom and semaglutide useful for the treatment of metabolic dysfunction‐associated steatohepatitis?
por: Stergios A. Polyzos, et al.
Publicado: (2026)

A review of multidisciplinary care in metabolic dysfunction‐associated steatohepatitis and cardiometabolic disease, with a focus on Canada
por: James Kim, et al.
Publicado: (2025)

Hepatic thyroid hormone receptor‐β signalling: Mechanisms and recent advancements in the treatment of metabolic dysfunction‐associated steatohepatitis
por: Stergios A. Polyzos, et al.
Publicado: (2024)

Efsubaglutide Alfa attenuates metabolic dysfunction‐associated steatohepatitis in mice with improvements in second harmonic generation‐derived fibrosis features
por: Yahao Wang, et al.
Publicado: (2026)

The latest evidence and guidance in lifestyle and surgical interventions to achieve weight loss in people with overweight or obesity
por: Iskandar Idris, et al.
Publicado: (2025)

Identification of growth differentiation factor 15 as an early predictive biomarker for metabolic dysfunction‐associated steatohepatitis: A nested case–control study of UK Biobank proteomic data
por: Hao Wang, et al.
Publicado: (2025)

Characterization of brain morphology associated with metabolic dysfunction‐associated steatotic liver disease in the UK Biobank
por: Wenxiao Fan, et al.
Publicado: (2025)

Associations between cuprotosis‐related genes and the spectrum of metabolic dysfunction‐associated fatty liver disease: An exploratory study
por: Hai‐Yang Yuan, et al.
Publicado: (2024)

Glycaemic control metrics and metabolic dysfunction–associated steatotic liver disease in children and adolescents with type 1 diabetes
por: Claudio Maffeis, et al.
Publicado: (2024)

Non‐invasive diagnosis of metabolic dysfunction‐associated steatotic liver disease: Current status, challenges, and future directions
por: Yuqing Ma, et al.
Publicado: (2025)

The effects of antihypertensive drugs on glucose metabolism
por: Zhe Li, et al.
Publicado: (2024)

Long‐term outcomes of metabolic surgery versus medical/lifestyle therapy on metabolic dysfunction‐associated fatty liver disease in adults with obesity and type 2 diabetes
por: Michelle D. Lundholm, et al.
Publicado: (2024)

An interpretable machine learning model for predicting metabolic dysfunction‐associated steatotic liver disease in patients with type 2 diabetes
por: Zhuolin Zhou, et al.
Publicado: (2025)

Caution in interpreting imaging‐based rankings in network meta‐analyses of metabolic dysfunction–associated steatotic liver disease therapies
por: Seoung Hoon Kim
Publicado: (2026)